About
Representation
View all Representation →Consultations- Digitisation Taskforce – Final Report
- FCA Consults on Fund Product Information and Cost Disclosure CP24/30 – ShareSoc Responds
- FRC Consults on UK Stewardship Code – ShareSoc Responds
- FCA Consultation – Modernising Redress
- HMRC Consultation – IHT on Pensions
- ShareSoc Evidence to Lords on FCA Enforcement
- ShareSoc supports FCA proposal for criminal background checks on owners and controllers of financial institutions
- UK ISA: ShareSoc submits consultation response
- FCA Consultation on Enforcement Practice & Transparency
- ShareSoc response to House of Commons Education Select Committee
- UKSA and ShareSoc Submission to Labour Party Review of Financial Services
- FCA Consultation GC23/2 Financial Promotions on Social Media
- VIEW ALL CONSULTATIONS
Education
Events
- Forums
Company
SYNAIRGEN PLC (SNG)
Blog posts
ShareSoc Growth Company Seminar Announcement
Post Date: September 3, 2014
The line-up for our next seminar at which public companies will be presenting on the 17th September is now complete and is given below. This event is in the City of London (at a different venue to normal), with registration starting at 4.00 pm. Four companies will be presenting this month and answering your questions, which are:
- Synairgen (SNG): A respiratory drug development company.
- Chapel Down Winery (CDGP): England's leading wine producer.
- Nature Group (NGR): Marine pollution and offshore waste processing.
- ServicePower (SVR): Field service software solutions.
Refreshments and a buffet ...
AGM Reports
Synairgen (SYN) AGM Report 2019
Post Date: June 27, 2019
The Synairgen 2019 AGM was held on Monday 2nd June at the offices of Fladgate LLP, 16 Great Queen Street, London.
For anyone who is unfamiliar with the company, Synairgen is an AIM listed UK based biotech company focused primarily on developing new treatments for Asthma, COPD and other respiratory diseases. The company floated on AIM in November 2004, issuing approximately 8m shares at 130p/share valuing the company at around £28m. There have been several placings since the IPO; the most recent ...
Synairgen (SNG) AGM 2018
Post Date: June 26, 2018
I attended the Synairgen AGM last Friday (June 22nd 2018), which was held at the offices of Fladgate LLP, 16 Great Queen Street, London.
For investors who is unfamiliar with the company, Synairgen is an AIM listed UK based biotech company focused primarily on developing new treatments for Asthma, COPD and other respiratory diseases. The company floated on AIM in November 2004, issuing approximately 8m shares at 130p/share valuing the company at around £28m. There have been several placings since the IPO ...
Synairgen (SNG) AGM 2016
Post Date: June 18, 2016
I attended the Synairgen AGM earlier this week (Tuesday June 14th) which was held at the offices of Fladgate LLP, 16 Great Queen Street, London.
For anyone who is unfamiliar with the company, Synairgen are an AIM listed UK based biotech focused on developing new treatments for Asthma, COPD and other respiratory diseases. Their current market cap is around £26M. Synairgen currently have one compound undergoing a confirmatory Phase II clinical study in asthma (funded entirely by Astra Zeneca) and a second ...
Become a free Associate ShareSoc member
Enter your email to sign up as a free Associate ShareSoc member and receive our emails. It takes a few seconds — and on the next page you'll have the option to customise your membership.